BRAF and familial atrioventricular septal defect: Finding BRAF v600e mutation in more than 50% of ECD patients [2] has led to the formulation of a clonal neoplastic origin for this disease, and the clinical efficacy of Vemurafenib (V600E-mutated BRAF protein inhibitor) in patients who harbour this mutation seems to confirm this theory [3,4].